FICOCYTE (Filgratism)

FICOCYTE (Filgratism)

FICOCYTE (Filgratism)

FICOCYTE (Filgratism)

FICOCYTE (Filgratism)

NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC.

Address:
Lot E2a-1, E2a-2 Saigon Hitech Park, Long Thanh My Ward, Thu Duc City, Ho Chi Minh City, VIETNAM
Lot I-5C Saigon Hitech Park, Tang Nhon Phu A Ward, Thu Duc City, Ho Chi Minh City, VIETNAM

Tel: (+84) 28 7108 9688

Fax: (+84) 283 730 9963

Email: info@nanogenpharma.com

FICOCYTE

Home Products FICOCYTE

FICOCYTE

COMPOSITION
Each prefilled syringe of 0.5 mL contains:
Active ingredients: Filgrastim...............30 MU
Excipients: Sodium hydroxide, Glacial acetic acid, Sorbitol as Sorbitol Syrup, Polysorbate 80, Water for Injections,
DESCRIPTION
Filgrastim (recombinant human granulocyte - colony stimulating factor, rHu G-CSF ) is produced by r-DNA technology in E.coli. 
Filgrastim is supplied as an injectable solution in prefilled syringes. Injectable solution is sterile, clear and colorless.
INDICATIONS
  • Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
  • Reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
  • Mobilisation of peripheral blood progenitor cells (PBPCs). 
  • In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5x109/L, and a history of severe or recurrent infections, long term administration of FICOCYTE is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events .
  • Treatment of persistent neutropenia (ANC≤1.0 x109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options to manage neutropenia are inappropriate.
  • The safety and efficacy of FICOCYTE are similar in adults and children receiving cytotoxic chemotherapy.
CONTRAINDICATION
  • Hypersensitivity to the active substance or to any of the excipients . FICOCYTE should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens. 
  • With severe congenital neutropenia (Kostman's syndrome) with abnormal cytogenetics.
STORAGE, SHELF LIFE, PACKING UNITS
Storage: Store at 2oC - 8oC. Do not freeze. Protect from light.
Shelf life: 24 months from manufacturing date. 
Packing units: Box of 01 prefilled syringe of solution for injection FICOCYTE 30 MU (0.5 mL)

Related products

Current product

PEGCYTE

Current product

PEGNANO

Current product

FERONSURE

Current product

NANOKINE